文献速递自身免疫性与大疱性皮肤病

寻常型天疱疮利妥昔单抗治疗后的时间结局

Temporal Outcomes after Rituximab Therapy for Pemphigus Vulgaris.
PubMed 文献 · J Invest Dermatol · 2021-10-26

该研究分析寻常型天疱疮患者接受利妥昔单抗后的临床与血清学时间结局。单周期后停口服系统治疗完全缓解率12个月为32.4%,36个月含追加周期达43.1%。抗Dsg3抗体滴度下降可预测完全缓解。

要点

  • 单周期利妥昔单抗后12个月完全缓解率32.4%,36个月含追加周期达43.1%
  • 3-9个月平均抗Dsg3滴度较基线下降>90.7%预测完全缓解敏感度94%
  • 6-9个月抗体滴度阴性者最终均达到停口服系统治疗完全缓解

核心结论

  • 利妥昔单抗治疗寻常型天疱疮后完全缓解率随时间累积,追加周期可提高缓解率。
  • 抗Dsg3抗体滴度早期下降可预测停口服系统治疗的完全缓解。

研究设计与样本

  • 报告寻常型天疱疮患者利妥昔单抗治疗后详细时间与血清学结局的分析。
  • 使用受试者工作特征曲线建立单周期利妥昔单抗后完全缓解的预测模型。

主要发现

  • 单周期利妥昔单抗后停口服系统治疗完全缓解最大患病率12个月为32.4%,36个月含追加周期为43.1%。
  • 3-9个月平均抗Dsg3 ELISA滴度较基线下降>90.7%预测完全缓解敏感度94%。
  • 3-9个月平均绝对滴度≤130 RU/ml预测完全缓解特异度96%。
  • 6-9个月抗体滴度阴性患者最终均达到停口服系统治疗完全缓解。

关键数值与推荐

  • 完全缓解定义为停口服系统治疗。
  • 单周期利妥昔单抗后完全缓解预测:3-9个月抗Dsg3滴度下降>90.7%敏感度94%。
  • 单周期利妥昔单抗后完全缓解预测:3-9个月平均绝对滴度≤130 RU/ml特异度96%。

临床怎么用

  • 利妥昔单抗治疗后监测3-9个月抗Dsg3抗体滴度变化有助于预测完全缓解。
  • 6-9个月抗体滴度阴性提示最终可能达到停口服系统治疗完全缓解。
  • 临床医生和患者可参考时间结局设定利妥昔单抗治疗后的预期。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Pemphigus vulgaris is an autoimmune blistering disease characterized by autoantibodies that target desmoglein adhesion proteins. Rituximab and corticosteroids are Food and Drug Administration‒approved therapies for pemphigus vulgaris. As newer treatments for pemphigus enter clinical trials, analysis of clinical and serologic outcomes after rituximab therapy as a function of time is essential to guide clinical trial design. In this study, we report detailed temporal and serologic outcomes of rituximab treatment of pemphigus vulgaris. The maximal prevalence of complete remission off oral systemic therapy after a single cycle of rituximab was 32.4% at 12 months or 43.1% by 36 months, including additional rituximab cycles. Using receiver operating characteristic curves to develop prediction models for complete remission after a single cycle of rituximab, >90.7% reduction in average desmoglein 3 ELISA titers from baseline to months 3‒9 was 94% sensitive, and an average absolute titer ≤130 RU/ml between months 3 and 9 was 96% specific, for achievement of complete remission off oral systemic therapy. All patients with negative titers at 6‒9 months ultimately achieved complete remission off oral systemic therapy. This dataset of clinical and serologic outcomes for patients with pemphigus vulgaris after rituximab therapy will facilitate clinical trial planning and also guide clinician and patient expectations after rituximab therapy.

来源:J Invest Dermatol,查看原文。版权归原作者所有。

引用

  1. Tovanabutra N, Bax CE, Feng R, et al. Temporal Outcomes after Rituximab Therapy for Pemphigus Vulgaris. J Invest Dermatol. 2021. PMID: 34710389. doi:10.1016/j.jid.2021.09.013

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。